NCT06542549 2024-08-07Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian CancerAnhui Provincial HospitalPhase 3 Not yet recruiting100 enrolled